# FOG-001 in Locally Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct05919264/  
OnCo record `nct05919264` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of FLOT, CAPOX, Nivolumab in colorectal cancer and metastatic cancer, run by Parabilis Medicines, Inc., now recruiting.

## Summary

FOG-001 in Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05919264 by Parabilis Medicines, Inc., with 619 participants planned, started 2023-05-23 and due to reach its primary completion in 2027-04-01. Interventions recorded: FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab. Conditions listed: Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05919264
- Phase: 1/2
- Setting: A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors
- Sponsor: Parabilis Medicines, Inc.
- Enrolled: 619

## Sources

- ClinicalTrials.gov NCT05919264: https://clinicaltrials.gov/study/NCT05919264

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Craniopharyngioma](https://onco.cc/cancers/craniopharyngioma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)

---
JSON: https://onco.cc/api/v1/entities/nct05919264.json